Abstract: Provided are a mixture of three species of Lactobacillus fermentum strain and Lactobacillus plantarum strain and use thereof. A composition according to one aspect including, as an active ingredient, a mixture of Lactobacillus fermentum strains GB102 and GB103 and Lactobacillus plantarum strain GB104; or a lysate or culture solution thereof, or an extract of the culture solution, can be usefully used for the prevention or treatment of muscle-related disorders or obesity by alleviating the decrease in grip strength induced by aging or reducing the change in intestinal microbial environment induced by aging.

Abstract: Provided are a Lactobacillus helveticus strain and a composition for preventing or treating inflammatory disease containing the same. The Lactobacillus helveticus strain (Accession No. KCTC 14110BP) according to the present invention alleviates symptoms of inflammatory bowel disease, such as weight loss and bowel length reduction, and it does not have side effects that have been seen with existing drug treatment. Therefore, the Lactobacillus helveticus strain can be effectively used for the treatment and prevention of inflammatory disease, particularly inflammatory bowel disease.

Abstract: Provided is a novel Lactobacillus Plantarum strain and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus Plantarum (Accession No. KCTC 14107BP) according to the present invention may inhibit fat accumulation in white adipose tissue, brown adipose tissue, and liver tissue. The Lactobacillus Plantarum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus Plantarum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus Plantarum strain may regulate a concentration of metabolic hormones in blood. Therefore, the Lactobacillus Plantarum strain may be usefully used to prevent or treat a metabolic disease.

Abstract: Provided is a novel Lactobacillus fermentum strain (Accession No. KCTC 14106BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation and increase anti-inflammatory cells in white adipose tissue. In addition, the Lactobacillus fermentum may effectively inhibit fat accumulation in brown adipose tissue and in liver tissue. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent or treat a metabolic disease such as obesity.

Abstract: There is provided a novel Lactobacillus fermentum strain (Accession No. KCTC 14105BP) and a composition for preventing or treating a metabolic disease including the same. A Lactobacillus fermentum according to the present invention may inhibit fat accumulation in white adipose tissue and increase anti-inflammatory cells. The Lactobacillus fermentum strain may exhibit excellent blood glucose improvement effect, and in particular, may reduce a fasting blood glucose level. The Lactobacillus fermentum strain may effectively ameliorate insulin resistance by improving glucose tolerance and increasing insulin sensitivity. In addition, the Lactobacillus fermentum strain may regulate a concentration of metabolic hormones and adipokines in blood. Therefore, the Lactobacillus fermentum strain may be usefully used to prevent and treat a metabolic disease such as obesity.

Abstract: A modified IgE Fc receptor having a high content of sialic acid and a pharmaceutical composition contains the modified IgE Fc receptor are disclosed. The polypeptide dimer having a high content of sialic acid not only has excellent safety and persistence in a body as compared with conventionally used anti-IgE antibodies, but also shows strong binding to IgE. Thus, the polypeptide has the advantage of an extended administration cycle. The polypeptide dimer is also an IgE single target substance, and unlike conventional anti-IgE antibodies to which the Fc of IgG1 is applied, does not bind to an Fc gamma receptor. The polypeptide dimer can be usefully used for the prevention or treatment of allergic diseases.